New Topoisomerase I mutations are associated with resistance to camptothecin
© Gongora et al; licensee BioMed Central Ltd. 2011
Received: 29 November 2010
Accepted: 27 May 2011
Published: 27 May 2011
Topoisomerase I (TOP1) is a nuclear enzyme that catalyzes the relaxation of supercoiled DNA during DNA replication and transcription. TOP1 is the molecular target of camptothecin and related drugs such as irinotecan and SN38 (irinotecan's active metabolite). Irinotecan is widely used as an anti-cancer agent in the treatment of metastatic colon cancer. However, its efficacy is often limited by the development of resistance.
We previously established several SN38 resistant HCT116-derived clones to study the mechanisms underlying resistance to SN38. Here, we investigated whether resistance to SN38 in these cell lines could be linked to the presence of TOP1 mutations and changes in its expression and activity. Functional analyses were performed on these cell lines challenged with SN38 and we specifically monitored the double strands breaks with γH2AX staining and replication activity with molecular combing.
In SN38 resistant HCT116 clones we identified three new TOP1 mutations, which are located in the core subdomain III (p.R621H and p.L617I) and in the linker domain (p.E710G) and are packed together at the interface between these two domains. The presence of these TOP1 mutations in SN38 resistant HCT116 cells did not modify TOP1 expression or intrinsic activity. Conversely, following challenge with SN38, we observed a decrease of TOP1-DNA cleavage complexes and a reduction in double-stranded break formation). In addition, we showed that SN38 resistant HCT116 cells present a strong decrease in the SN38-dependent asymmetry of replication forks that is characteristic of SN38 sensitive HCT116 cells.
These results indicate that the TOP1 mutations are involved in the development of SN38 resistance. We hypothesize that p.L617, p.R621 and p.E710 TOP1 residues are important for the functionality of the linker and that mutation of one of these residues is sufficient to alter or modulate its flexibility. Consequently, linker fluctuations could have an impact on SN38 binding by reducing the enzyme affinity for the drug.
Irinotecan (CPT-11), a semi-synthetic water-soluble derivative of camptothecin, is widely used for the treatment of metastatic colon cancer in first- and second-line therapies . CPT-11 is a pro-drug which is converted by carboxylesterases into the active form SN38. Like other camptothecin derivatives, SN38 exerts its cytotoxic activity through inhibition of Topoisomerase 1 (TOP1). Human TOP1 is a nuclear enzyme responsible for the relaxation of supercoiled DNA, which is needed for DNA replication, transcription and chromatin condensation [2, 3]. TOP1 first introduces a nick in one strand of duplex DNA and then religates the TOP1-linked DNA break. SN38 interferes with TOP1 activity by inhibiting the religation step and induces the formation of stable covalent ternary complexes at DNA breakage points . As a consequence, collision with the replication machinery produces double strand breaks at the replication fork .
The most frequently reported cellular mechanisms of resistance to CPT-11 include reduced intracellular drug accumulation (mediated by ABC transporters) [6, 7], alterations in CPT-11 and SN38 metabolism , quantitative and qualitative alterations of the TOP1 protein [9–11] and alterations in the cellular response to ternary complex formation that ultimately lead to repair of DNA damage or cell death [3, 12].
TOP1 mutations that confer resistance to camptothecin derivatives have been identified in mammalian cells and yeast [13–16]. Most of them are located close to the active site of the enzyme or clustered in two regions of the core domain . Recently, Benedetti and colleagues showed that the p.A653P mutation limits the flexibility of the linker domain . Studies of clinical specimens are needed to determine whether such mutations can be found also in patients and are involved in chemotherapy resistance. Among the few studies that have investigated the presence of TOP1 mutations in clinical samples [19–21], only one reported two point mutations (p.W736X and p.G737S on the same allele) in tumor tissues from a patient treated with CPT-11 . However, this result has never been confirmed.
We have previously established SN38 resistant clones from the human colon carcinoma cell line HCT116 to investigate the mechanisms that lead to resistance to SN38 [7, 22]. In this study, we identified three new TOP1 mutations in these clones. Moreover, we show that, following treatment with SN38, DNA cleavage complexes and DNA double strand break formation are reduced in SN38 resistant cells as well as the SN38-induced asymmetry of the replication fork that is typical of SN38 sensitive cells. Finally, the localization of these new TOP1 mutations suggests that they could influence the linker flexibility and possibly alter TOP1/SN38 interaction.
Drug sensitivity assay and calculation of the doubling time
Cell growth inhibition and cell viability after SN38 treatment were assessed using the Sulforhodamine B (SRB) and the clonogenic assays as previously described . To calculate the doubling time (DT), cells (15 ×104) were seeded in seven identical 25 cm2 flasks for each counting experiment. Then, every 24 hours the viable cells of one flask were counted with a hemocytometer after Trypan blue staining. DT was calculated during exponential growing phase as following: DT = h*ln(2)/ln(c2/c1); h = time point in hours; c1 and c2 = cell concentration at the beginning and at the end of h.
Whole cell lysates were prepared as previously described . Proteins from the extracts (105 cells per lane) were electrophoretically separated on 10% SDS-PAGE, then electro-transferred onto polyvynilidene difluoride membranes (Amersham Biosciences, Buckinghamshire, UK). Membranes were incubated with the appropriate primary antibody: polyclonal anti-Top1 , anti-ABCG2  anti-GAPDH (clone 6C5) antibody from Millipore (Billerica, MA, USA),. Secondary antibodies were peroxidase-conjugated anti-mouse (Sigma-Aldrich, St. Louis, MO, USA) and anti-rabbit anti-sera (Sigma-Aldrich, Saint-Louis, MO, USA).
5'-CTCAGCCGTTTCTGGAGTCT-3' and 5'-TCAGCATCATCCTCATCTCG;
5'-CGAAAAGAGGAAAAGGTTC-3' and 5'-GGGCTCAGCTTCATGACTTT;
5'-CCACCATATGAGCCTCTTCC-3' and 5'-CCTTGTTATCATGCCGGACT;
5'-AGAGCCTCCTGGACTTTTCC-3' and 5'- GACCATCCAACTCTGGGTGT-3';
5'- TTCGTGTGGAGCACATCAAT-3' and 5'- GACCTTGGCATCAGCCTTAG-3';
5'-CGAGCTGTTGCAATTCTTTG-3' and 5'- ACCACACTGTTCCTCTTCAC-3'.
Purified PCR products were then sequenced using the same sense primers by the dideoxynucleotide method using the MWG Biotech sequencing service.
Top1 cDNA cloning
The TOP1 region that contains the p.R621H and p.E710G mutations was PCR amplified using the 5'-AGAGCCTCCTGGACTTTTCC-3' and 5'- ACCACACTGTTCCTCTTCAC-3 primers from HCT116-SN6 cDNA. The amplicon was digested with Hind III and Hae III and then cloned in Hind III-EcoR V digested and dephosphorylated pcDNA3 plasmid. Ligation was transformed in C-Max5αF' cells that were grown on LB with 100 μg/ml ampicillin for 16 h at 37°C. Transformants were selected by PCR screening; PCR products were then purified and sequenced.
High Resolution Melting (HRM) analysis
Primers were designed using the LightCycler Probe Design Software 2.0 and were: 5'-GATGAGAACATCCCAGCGA-3' and 5'-GCAAGTTCATCATAGACTTCTCAA-3' for the detection of the p.R621H mutation; 5'-CAGTTGATGAAGCTGGAAGT-3' and 5'-CTGTGATCCTAGGGTCCAGAT-3' for the detection of the p.E710G mutation. HRM analysis of cDNA samples or PCR products (amplification of the TOP1 region that contains the p.R621H and p.E710G mutations, as described in the previous paragraph "DNA cloning") were carried out in duplicate using the LightCycler 480 System (Roche, Indianapolis, IN, USA). The reaction mixture in a 10 μl final volume consisted of 0.2 μM of each primer, 5 μL of master mix, which contained the Taq polymerase, nucleotides and the ResoLight dye (Roche, Indianapolis, IN, USA), 3 mM of MgCl2 and 10 ng of cDNA. The PCR program consisted of an initial denaturation-activation step at 95°C for 10 min followed by 40 cycles (denaturation at 95°C for 15 s, annealing at 58°C 15 s and elongation at 72°C for 15 s with reading of the fluorescence; acquisition mode: single). The melting program included three steps: denaturation at 95°C for 1 min, renaturation at 40°C for 1 min to encourage heteroduplex formation and melting over the desired temperature range (76-92°C unless otherwise stated) to obtain the HRM curve data at a rate of 25 acquisitions per 1°C. The melting curve analysis carried out by the Gene-Scanning Software comprises three steps: normalization of the melting curves by equalizing the initial fluorescence and the remaining fluorescence after DNA dissociation to 100% and 0%, respectively; shifting of the temperature axis of the normalized melting curves to the point where the entire double-stranded DNA is completely denatured; and finally, analysis of the differences in the melting-curve shapes by subtracting the curves of wild type and mutated DNAs (difference plot).
Immunocomplex of enzyme (ICE) bioassay
Covalent TOP1-DNA adducts were isolated using the ICE bioassay according to a previously published procedure . Briefly, 106 cells were lysed with 1% sarcosyl and layered on step gradients containing CsCl solutions (2 mL each) of the following densities: 1.82, 1.72, 1.50, and 1.45. Tubes were centrifuged at 165,000 × g in a Beckman SW40 rotor for 17 h at 20°C and 0.5 ml fractions were collected from the bottom of the tubes. DNA-containing fractions were pooled, normalized for DNA concentration, diluted with an equal volume of 25 mM NaPO4 buffer (pH 6.5) and applied to Immobilon-P membranes with a slot-blot vacuum manifold. TOP1-DNA adducts were visualized by immunostaining using the polyclonal anti-TOP1 antibody from Abcam (ab-3825, Cambridge, MA, USA).
Phosphorylated H2AX quantification by flow cytometry analysis
Cells were seeded in 25 cm2 flasks (2 × 105 cells/flask). After a 48-hour rest, cells were incubated with 0.5 μM SN38 for 20 hours. One million cells were pelleted, fixed and permeabilized according to the H2AX Phosphorylation Assay Kit (Upstate Biotechnology, Lake Placid, NY, USA) and incubated with the anti-phospho-Histone H2A.X FITC conjugated antibody to detect Histone H2A.X phosphorylation at Serine 139. Analyses were done using an Epics Coulter flow cytometer (Beckman, Ramsey, MN, USA) and results quantified with the Expo 32 analysis software (Coulter, Ramsey, MN, USA).
Phosphorylated H2AX detection by fluorescence microscopy
Cells growing on chamber slides were treated with 0.5 μM SN38 for 20 hours. Slides were fixed with 4% paraformaldhehyde/PBS at room temperature for 10 min, permeabilized with 0.1% Triton X100/PBS at room temperature for 10 min and blocked with PBS containing 5% BSA at 37°C for 30 min. Slides were incubated with 1/100 diluted mouse anti-phospho-histone H2AX (ser139) FITC conjugated antibody (Upstate Biotechnology, Lake Placid, NY, USA) and DAPI was used to stain the nucleus. Stained cells were mounted in Moviol, and images were recorded using a 63XNA objective on a Leica inverted microscope.
DNA combing was performed as previously described [25, 26]. DNA fibers from the different HCT116 clones were extracted in agarose plugs immediately after labeling and were stretched on silanized coverslips. In fork recovery experiments, CldU and IdU were detected with the anti-BrdU antibodies BU1/75 (AbCys, Paris, France) and BD44 (Becton Dickinson, Franklin Lakes, NJ, USA), respectively. DNA fibers were analyzed on a Leica DM6000B microscope equipped with a CoolSNAP HQ CCD camera (Roper Scientifics, Sarasota, Florida, USA) and a 40x objective. Image acquisition was performed with MetaMorph (Roper Scientifics, Sarasota, Florida, USA). Representative images of DNA fibers were assembled from different fields of view and processed as described  with Adobe Photoshop.
Cell cycle distribution
To determine the cell cycle distribution, SN38 sensitive and resistant, exponentially growing HCT116 cells were plated (1 × 105 cells) in 6-well plates and 24 hours later cells were exposed to 20 nM SN38. After 24 hours of treatment, untreated and treated cells were washed in ice cold PBS, fixed in 70% ethanol and labeled with 40 μg/ml propidium iodide (Sigma-Aldrich, Saint-Louis, MO, USA) containing 100 μg/ml RNase A (Sigma-Aldrich, Saint-Louis, MO, USA) at 37°C for 1.5 hours. Cell cycle distribution was then determined with a FACScan fluorescence-activated cell sorter (Becton Dickinson, Franklin Lakes, MD, USA) using the FL-2 channel. Cells were gated on a dot plot that displayed DNA pulse-width versus DNA-pulse area to exclude aggregated cells. Cell cycle distributions were illustrated using the WinMDI2.8 histogram analysis software (Phoenix Flow Systems, San Diego, CA, USA) and quantified using Multicycle (DNA-cell cycle analysis software distributed by Phoenix Flow Systems, San Diego, CA, USA).
Colorectal cancer patients
Normal and cancer colon samples and hepatic metastases were obtained from 45 advanced colorectal cancer patients with synchronous hepatic metastases who were followed at the CRLC Val d'Aurelle, Montpellier, France. The clinical features of these patients have been described elsewhere . All patients underwent surgery for primary tumor resection during which hepatic biopsies were also taken. Treated metastases samples were obtained from patients who were diagnosed with unresectable hepatic metastases and had received CPT-11-based therapy that ended less than 2 months before metastasis resection.
Characterization of the SN38 resistant HCT116 clones
To obtain SN38 resistant clones, we exposed the colon adenocarcinoma cell line HCT116 to increasing concentrations of SN38 (Figure 1A). All five resistant clones grew slower than the sensitive HCT116-s clone and consequently their doubling times were 1.2- to 2.1-fold higher than in HCT116-s cells (Figure 1B). The resistant clones showed different in vitro level of resistance to SN38 as indicated by the 6- to 56- fold increase of their IC50 value (determined by SRB assay) in comparison to the sensitive HCT116-s cell line (Figure 1B). We have already shown for HCT116-SN50, that high level of resistance to SN38 is associated with over-expression of the ABCG2 efflux pump . This finding was confirmed in the HCT116-A2 clone which displayed a comparable high level of resistance to SN38 (Figure 1C). Conversely, the three other resistant clones did not express ABCG2, suggesting that these clones have developed different drug resistant mechanism. To exclude other efflux mechanisms, the expression of two other efflux proteins known to transport camptothecin derivatives, Pgp and MRP1, was assessed by western blotting. Compared to the MCF7-R positive control, none of the clones displayed any detectable amount of PgP or MRP1 (Additional file 1, Figure S1). We also evaluated by western blotting the expression of Topoisomerase I (TOP1), which is often involved in resistance to camptothecin derivatives. However, its expression (Figure 1C) did not vary significantly in SN38 sensitive and resistant HCT116 cells.
Resistant HCT116 cell lines contain novel TOP1 mutations
On the other hand, the highly resistant clones HCT116-SN50 and HCT116-A2, which over-express ABCG2, both contained a homozygous mutation (C→A transversion), which resulted in a Leucine to Isoleucine substitution at position 617 of the TOP1 protein (Figure 2A). This mutation is located in helix 17 just one turn before the p.R621H mutation found in the moderately resistant clones. Despite its conservative nature, this mutation could also affect the packing of helix 17 and 19 (Figure 2B).
Trapping of DNA cleavage complexes is reduced in SN38 resistant HCT116 cells
DNA double strand break formation is reduced in SN38 resistant HCT116 cells
TOP1 mutations decrease SN38-induced replication fork asymmetry
TOP1 mutations decrease SN38-induced cell cycle perturbations
The p.R621H, p.L617I and p.E710G TOP1 mutations are not detectable in tissue samples from colorectal cancer patients
In this study, we have characterized five SN38 resistant clones derived from the HCT116 adenocarcinoma cell line. They all have a reduced growth rate in comparison to the sensitive HCT116-s cell line in agreement with our previous data on one of the SN38 resistant clones (HCT116-SN6) , thus suggesting that their slower growth rate may account as one of the SN38 resistance mechanisms. Moreover, we identified three new mutations in the TOP1 gene that could be involved in the cytotoxicity mechanisms of SN38 and CPT-11. Specifically, the point mutations p.R621H and p.E710G are present in moderately resistant clones, whereas the p.L617I mutation is found in the highly resistant clones that also over-express ABCG2.
We then investigated the effects of these mutations on TOP1 and found that, in presence of SN38, both TOP1 cleavage complexes and DSB formation were reduced. Moreover, DNA combing revealed that SN38-induced asymmetry in replication forks was decreased. The asymmetry of sister forks due to the SN38-induced DNA DSB reported here confirms the CPT-11 (or SN38) inhibition of origin firing and fork progression . Indeed, discontinuous fork progression is the consequence of a collision between the replication fork and SN38-stabilized TOP1-cleavable complexes resulting in forks arrest and breakage. Moreover, TOP1 has been recently shown to be involved in the progression of replication forks since TOP1 deficient cells display slower replication fork progression and more pausing or stalling . All these molecular results confirm that in resistant cells treated with camptothecin derivatives there is a decrease of the main mechanism that generates DNA damage that is TOP1 replication-mediated DNA DSB.
The decrease of cleavage complexes could be explained by 1) modified intrinsic catalytic activity of TOP1, inducing decreased rates of DNA cleavage or increased rates of re-ligation and leading to diminution of covalent TOP1-DNA intermediates or 3) reduced affinity of the TOP1-DNA covalent complex for the drug. The first possibility is not likely as we previously showed that TOP1 intrinsic catalytic activity is comparable in the resistant HCT116-SN6 and sensitive HCT116-s cells . Moreover, we show here that the basal level of TOP1 cleavage complexes is similar in all the resistant clones, and they contain an equivalent number of DNA DSB and display similar fork asymmetry than the sensitive cells, showing that TOP1 activity is not affected in the untreated resistant clones. Therefore the most probable mechanism is a decrease in TOP1 affinity for CPT-11 and SN38 due to the mutations. The fact that the three mutations have apparently the same effect can be easily explained by their close proximity in the protein. Indeed, the three residues are packed together, forming part of the interface between helix 17 of the core subdomain III (p.R621H and p.L617I) and helix 19 of the linker domain (p.E710G). Because of this close proximity, we can speculate that whatever the mutation, the effect on the interaction between the core subdomain III and the linker region will be comparable.
Human TOP1 is arranged in four domains: the NH2-terminal domain (residues 1-214), the core domain (residues 215-635), that can be divided in subdomains I, II and III, the linker domain (residues 636-712) and the COOH-terminal domain (residues 713-765). The poorly conserved linker domain, which connects the core and COOH-terminal domains, is highly flexible  and is dispensable for the catalytic activity . It has been proposed that the lack of a functional linker accounts for the reduced sensitivity to CPT-11 [33, 34]. Among the TOP1 mutations known to be involved in CPT-11 resistance only one mutation (p.A653P) was found in the linker domain . The authors suggested that, by increasing the linker domain flexibility, this mutation may alter the conformational changes imposed by drug binding, giving rise to a CPT-11 resistant enzyme. The three mutations described here could confer a resistance phenotype by a comparable mechanism. Indeed, the largest conformational flexibility of TOP1 is between the core subdomain III and the linker domain, which can rotate and shift up to 2.5 Å and 4.6 Å from one to the other. The three mutations are at positions that are involved in the interaction between these two domains but are not disordered in the structure - except slightly in the case of glutamate 710  and could thus be stabilizing residues. As a consequence their mutation could modulate the structural flexibility of the linker and the linker fluctuations could reduce the enzyme affinity for the drug [18, 35].
Our knowledge on CPT-11 resistance mechanisms is largely based on in vitro studies. Indeed, several cell lines selected for resistance to CPT-11 have been described and many TOP1 mutations that confer resistance to CPT-11 have been identified in these cells (for instance p.F361S, p. R364H, p.E418L, p.G503S, p.D533G, p.A653P, and p.N722S) [17, 36, 37]. However, such TOP1 mutations have never been confirmed in clinical samples. This is also the case of the three new mutations described here. Since we have shown that all the resistant cells with TOP1 mutations display reduced growth rate, we could imagine that in a heterogenic tumoral population, cells that carry a TOP1 mutation could be overtaken by the sensitive cells as soon as irinotecan selection pressure is lifted. This would explain why it is so easy to identify TOP1 mutations in cellular models, but so difficult to confirm them in clinical samples.
In this report, we describe three new TOP1 mutations that are involved in vitro in the development of resistance to camptothecin derivatives. These mutations seem to affect TOP1/drug interaction by reducing the affinity or the binding of the drug.
This work was supported by funds from Sanofi Aventis and from the INSERM.
- Rougier P, Mitry E: Colorectal cancer chemotherapy: irinotecan. Semin. Oncol. 2000, 27: 138-43.PubMedGoogle Scholar
- Wang JC: Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002, 3: 430-40. 10.1038/nrm831View ArticlePubMedGoogle Scholar
- Leppard JB, Champoux JJ: Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma. 2005, 114: 75-85. 10.1007/s00412-005-0345-5View ArticlePubMedGoogle Scholar
- Pommier Y, Pourquier P, Fan Y, Strumberg D: Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta. 1998, 1400: 83-105.View ArticlePubMedGoogle Scholar
- Furuta T, Takemura H, Liao ZY, Aune GJ, Redon C, Sedelnikova OA, Pilch DR, Rogakou EP, Celeste A, Chen HT, Nussenzweig A, Aladjem MI, Bonner WM, Pommier Y: Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem. 2003, 278: 20303-12. 10.1074/jbc.M300198200View ArticlePubMedGoogle Scholar
- Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD, Kohno S: Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem. Biophys. Res. Commun. 2001, 280: 1216-23. 10.1006/bbrc.2001.4267View ArticlePubMedGoogle Scholar
- Candeil L, Gourdier I, Peyron D, Vezzio N, Copois V, Bibeau F, Orsetti B, Scheffer GL, Ychou M, Khan QA, Pommier Y, Pau B, Martineau P, Del Rio M: ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. Int. J. Cancer. 2004, 109: 848-54. 10.1002/ijc.20032View ArticlePubMedGoogle Scholar
- Takahashi T, Fujiwara Y, Yamakido M, Katoh O, Watanabe H, Mackenzie PI: The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn. J. Cancer Res. 1997, 88: 1211-17.View ArticlePubMedGoogle Scholar
- Sugimoto Y, Tsukahara S, Oh-hara T, Isoe T, Tsuruo T: Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 1990, 50: 6925-30.PubMedGoogle Scholar
- Woessner RD, Eng WK, Hofmann GA, Rieman DJ, McCabe FL, Hertzberg RP, Mattern MR, Tan KB, Johnson RK: Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol. Res. 1992, 4: 481-8.PubMedGoogle Scholar
- Wang LF, Ting CY, Lo CK, Su JS, Mickley LA, Fojo AT, Whang-Peng J, Hwang J: Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Res. 1997, 57: 1516-22.PubMedGoogle Scholar
- Pommier Y, Redon C, Rao VA, Seiler JA, Sordet O, Takemura H, Antony S, Meng L, Liao Z, Kohlhagen G, Zhang H, Kohn KW: Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat. Res. 2003, 532: 173-203.View ArticlePubMedGoogle Scholar
- Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L, Redinbo MR: Mechanisms of Camptothecin Resistance by Human Topoisomerase I Mutations. Journal of Molecular Biology. 2004, 339: 773-84. 10.1016/j.jmb.2004.03.077View ArticlePubMedGoogle Scholar
- Arakawa Y, Suzuki H, Saito S, Yamada H: Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells. Mol Cancer Ther. 2006, 5: 502-8. 10.1158/1535-7163.MCT-05-0246View ArticlePubMedGoogle Scholar
- van der Merwe M, Bjornsti M: Mutation of Gly721 Alters DNA Topoisomerase I Active Site Architecture and Sensitivity to Camptothecin. J. Biol. Chem. 2008, 283: 3305-15.View ArticlePubMedGoogle Scholar
- Losasso C, Cretaio E, Fiorani P, D'Annessa I, Chillemi G, Benedetti P: A single mutation in the 729 residue modulates human DNA topoisomerase IB DNA binding and drug resistance. Nucleic Acids Res. 2008, 36: 5635-44. 10.1093/nar/gkn557PubMed CentralView ArticlePubMedGoogle Scholar
- Pommier Y, Pourquier P, Urasaki Y, Wu J, Laco G: Topoisomerase I inhibitors: selectivity and cellular resistance. Drug Resist Updat. 1999, 2: 307-18. 10.1054/drup.1999.0102View ArticlePubMedGoogle Scholar
- Fiorani P, Bruselles A, Falconi M, Chillemi G, Desideri A, Benedetti P: Single Mutation in the Linker Domain Confers Protein Flexibility and Camptothecin Resistance to Human Topoisomerase I. J. Biol. Chem. 2003, 278: 43268-75. 10.1074/jbc.M303899200View ArticlePubMedGoogle Scholar
- Ohashi N, Fujiwara Y, Yamaoka N, Katoh O, Satow Y, Yamakido M: No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer. Jpn J Cancer Res. 1996, 87: 1280-7.View ArticlePubMedGoogle Scholar
- Takatani H, Oka M, Fukuda M, Narasaki F, Nakano R, Ikeda K, Terashi K, Kinoshita A, Soda H, Kanda T, Schneider E, Kohno S: Gene Mutation Analysis and Quantitation of DNA Topoisomerase I in Previously Untreated Non-small Cell Lung Carcinomas. Cancer Science. 1997, 88: 160-5. 10.1111/j.1349-7006.1997.tb00361.x.Google Scholar
- Tsurutani J, Nitta T, Hirashima T, Komiya T, Uejima H, Tada H, Syunichi N, Tohda A, Fukuoka M, Nakagawa K: Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer. 2002, 35: 299-304. 10.1016/S0169-5002(01)00425-1View ArticlePubMedGoogle Scholar
- Gongora C, Candeil L, Vezzio N, Copois V, Denis V, Breil C, Molina F, Fraslon C, Conseiller E, Pau B, Martineau P, Del Rio M: Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38. Cancer Biol. Ther. 2008, 7: 822-32. 10.4161/cbt.7.6.5838View ArticlePubMedGoogle Scholar
- Soret J, Gabut M, Dupon C, Kohlhagen G, Stévenin J, Pommier Y, Tazi J: Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in Mammalian cells lacking topoisomerase I. Cancer Res. 2003, 63: 8203-11.PubMedGoogle Scholar
- Subramanian D, Kraut E, Staubus A, Young DC, Muller MT: Analysis of topoisomerase I/DNA complexes in patients administered topotecan. Cancer Res. 1995, 55: 2097-103.PubMedGoogle Scholar
- Michalet X, Ekong R, Fougerousse F, Rousseaux S, Schurra C, Hornigold N, Slegtenhorst MV, Wolfe J, Povey S, Beckmann JS, Bensimon A: Dynamic Molecular Combing: Stretching the Whole Human Genome for High-Resolution Studies. Science. 1997, 277: 1518-23. 10.1126/science.277.5331.1518View ArticlePubMedGoogle Scholar
- Versini G, Comet I, Wu M, Hoopes L, Schwob E, Pasero P: The yeast Sgs1 helicase is differentially required for genomic and ribosomal DNA replication. EMBO J. 2003, 22: 1939-49. 10.1093/emboj/cdg180PubMed CentralView ArticlePubMedGoogle Scholar
- Pasero P, Bensimon A, Schwob E: Single-molecule analysis reveals clustering and epigenetic regulation of replication origins at the yeast rDNA locus. Genes Dev. 2002, 16: 2479-84. 10.1101/gad.232902PubMed CentralView ArticlePubMedGoogle Scholar
- Del Rio M, Molina F, Bascoul-Mollevi C, Copois V, Bibeau F, Chalbos P, Bareil C, Kramar A, Salvetat N, Fraslon C, Conseiller E, Granci V, Leblanc B, Pau B, Martineau P, Ychou M: Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan. J Clin Oncol. 2007, 25: 773-80. 10.1200/JCO.2006.07.4187PubMed CentralView ArticlePubMedGoogle Scholar
- Seiler JA, Conti C, Syed A, Aladjem MI, Pommier Y: The intra-S-phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses. Mol Cell Biol. 2007, 27: 5806-18. 10.1128/MCB.02278-06PubMed CentralView ArticlePubMedGoogle Scholar
- Tuduri S, Crabbé L, Conti C, Tourrière H, Holtgreve-Grez H, Jauch A, Pantesco V, De Vos J, Thomas A, Theillet C, Pommier Y, Tazi J, Coquelle A, Pasero P: Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription. Nat Cell Biol. 2009, 11: 1315-24. 10.1038/ncb1984PubMed CentralView ArticlePubMedGoogle Scholar
- Erali M, Voelkerding KV, Wittwer CT: High resolution melting applications for clinical laboratory medicine. Exp. Mol. Pathol. 2008, 85: 50-8. 10.1016/j.yexmp.2008.03.012PubMed CentralView ArticlePubMedGoogle Scholar
- Redinbo MR, Stewart L, Champoux JJ, Hol WG: Structural flexibility in human topoisomerase I revealed in multiple non-isomorphous crystal structures. J Mol Biol. 1999, 292: 685-696. 10.1006/jmbi.1999.3065View ArticlePubMedGoogle Scholar
- Stewart L, Ireton GC, Champoux JJ: A Functional Linker in Human Topoisomerase I Is Required for Maximum Sensitivity to Camptothecin in a DNA Relaxation Assay. J. Biol. Chem. 1999, 274: 32950-60. 10.1074/jbc.274.46.32950View ArticlePubMedGoogle Scholar
- Losasso C, Cretaio E, Palle K, Pattarello L, Bjornsti M, Benedetti P: Alterations in Linker Flexibility Suppress DNA Topoisomerase I Mutant-induced Cell Lethality. J. Biol. Chem. 2007, 282: 9855-64. 10.1074/jbc.M608200200View ArticlePubMedGoogle Scholar
- Palle K, Montaudon D, Del Rio M, Tautu M, Martineau P, Benedetti P, Pourquier P, Bjornsti MA: Residue Arg621 stabilizes a hydrogen bond network in DNA topoisomerase I necessary for colon cancer cell sensitivity to irinotecan. Proc Am Assoc Cancer Res. 2009, 2009. Abstract nr 1695, Denver, CO. Philadelphia (PA): AACRGoogle Scholar
- Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Stewart L: The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci. USA. 2002, 99: 15387-15392. 10.1073/pnas.242259599PubMed CentralView ArticlePubMedGoogle Scholar
- Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L, Redinbo MR: Mechanisms of camptothecin resistance by human topoisomerase I mutations. J. Mol. Biol. 2004, 339: 773-784. 10.1016/j.jmb.2004.03.077View ArticlePubMedGoogle Scholar
- The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC: : http://www.pymol.org/
- Persistence of Vision Raytracer (Version 3.6.1) [Computer software] : http://www.povray.org/
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.